January 9, 2025 - 19:58

Attorneys Heidi Urness and Rudy Cerone have shared insights into the opportunities available within the realm of distressed marijuana businesses. As the cannabis industry continues to evolve, many companies face significant challenges, creating a landscape ripe for investment and strategic partnerships.
Urness emphasizes the importance of due diligence when evaluating these businesses. She notes that understanding the underlying reasons for distress—be it financial mismanagement, regulatory hurdles, or market competition—is crucial in determining whether a business can be turned around.
Cerone adds that potential investors should look for signs of resilience and adaptability within a company. Factors such as a strong brand presence, a loyal customer base, and innovative product offerings can indicate a business's potential for recovery.
In a market that remains volatile, Urness and Cerone advocate for a cautious yet optimistic approach, encouraging stakeholders to recognize the unique opportunities that distressed marijuana businesses can offer.
May 16, 2026 - 00:10
Blake's Snow Shack owned by man with Down syndrome in Texas turns 10In the small North Texas town of Sanger, a beloved local business is marking a sweet anniversary. Blake`s Snow Shack, a shaved ice stand owned and operated by a man with Down syndrome, is turning...
May 15, 2026 - 04:31
SBA Launches Small Business Pitch Competition » CBIAThe U.S. Small Business Administration has announced a new pitch competition aimed at companies that show strong innovation and have a track record of using SBA-backed financing tools. The contest...
May 14, 2026 - 01:02
INOVIO Reports First Quarter 2026 Financial Results and Recent Business HighlightsINOVIO has released its financial results for the first quarter of 2026, alongside a summary of recent business developments. The company`s primary focus remains on the regulatory path for its lead...
May 13, 2026 - 04:15
Curis Provides First Quarter 2026 Business UpdateCuris, Inc., a biotechnology company advancing the development of its lead drug candidate emavusertib, provided a business update for the first quarter of 2026. The company is focused on...